Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone484-801-4670
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees28
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions
What is Marinus Pharmaceuticals' stock symbol?
Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."
How were Marinus Pharmaceuticals' earnings last quarter?
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) released its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.01. View Marinus Pharmaceuticals' Earnings History.
When is Marinus Pharmaceuticals' next earnings date?
What price target have analysts set for MRNS?
7 analysts have issued 12-month target prices for Marinus Pharmaceuticals' shares. Their forecasts range from $1.70 to $29.00. On average, they anticipate Marinus Pharmaceuticals' stock price to reach $11.81 in the next year. This suggests a possible upside of 743.9% from the stock's current price. View Analyst Price Targets for Marinus Pharmaceuticals.
What is the consensus analysts' recommendation for Marinus Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marinus Pharmaceuticals.
What are Wall Street analysts saying about Marinus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Marinus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. " (10/10/2019)
- 2. LADENBURG THALM/SH SH analysts commented, "We find this is the right and not completely unexpected decision considering his enthusiasm in developing ganaxolone, his broad experience in companies and as an investor, as well as the need for strong stewardship at this time." (8/9/2019)
- 3. Cantor Fitzgerald analysts commented, "Given the compelling Phase 2 data announced in CDD, market size potential in PPD (with positive interim data reported in 4Q18), and undervaluation relative to peers, we believe Marinus shares offer a compelling risk-reward profile. Valuation Summary We arrive at our 12-month PT of $22/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from ganaxolone for the treatment of postpartum depression and CDKL5 deficiency disorder." (5/1/2019)
Has Marinus Pharmaceuticals been receiving favorable news coverage?
News coverage about MRNS stock has been trending neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Marinus Pharmaceuticals earned a news impact score of 0.4 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Marinus Pharmaceuticals.
Are investors shorting Marinus Pharmaceuticals?
Marinus Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totalling 4,340,000 shares, an increase of 47.6% from the August 30th total of 2,940,000 shares. Based on an average daily trading volume, of 1,720,000 shares, the short-interest ratio is currently 2.5 days. Currently, 9.3% of the company's stock are sold short. View Marinus Pharmaceuticals' Current Options Chain.
Who are some of Marinus Pharmaceuticals' key competitors?
Some companies that are related to Marinus Pharmaceuticals include Dermira (DERM), Theratechnologies (THERF), Karuna Therapeutics (KRTX), Urovant Sciences (UROV), Avid Bioservices (CDMO), Rigel Pharmaceuticals (RIGL), OptiNose (OPTN), Puma Biotechnology (PBYI), Geron (GERN), Ardelyx (ARDX), Dynavax Technologies (DVAX), Cyclerion Therapeutics (CYCN), BIOFRONTERA AG/ADR (BFRA), resTORbio (TORC) and Kindred Biosciences (KIN).
What other stocks do shareholders of Marinus Pharmaceuticals own?
Who are Marinus Pharmaceuticals' key executives?
Marinus Pharmaceuticals' management team includes the folowing people:
- Mr. Edward F. Smith, VP, CFO, Treasurer & Sec. (Age 48)
- Mr. Christopher Michael Cashman, CEO, Pres & Director (Age 62)
- Dr. Lorianne K. Masuoka, Chief Medical Officer (Age 58)
- Dr. Scott Braunstein, Exec. Chairman (Age 56)
- Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations
How do I buy shares of Marinus Pharmaceuticals?
Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Marinus Pharmaceuticals' stock price today?
One share of MRNS stock can currently be purchased for approximately $1.40.
How big of a company is Marinus Pharmaceuticals?
Marinus Pharmaceuticals has a market capitalization of $73.61 million. The biopharmaceutical company earns $-36,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Marinus Pharmaceuticals employs 28 workers across the globe.View Additional Information About Marinus Pharmaceuticals.
What is Marinus Pharmaceuticals' official website?
How can I contact Marinus Pharmaceuticals?
Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 100, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]
MarketBeat Community Rating for Marinus Pharmaceuticals (NASDAQ MRNS)
| Community Ranking: | | 2.8 out of 5 ( ) |
| Outperform Votes: | | 305 (Thanks for Voting!) |
| Underperform Votes: | | 247 (Thanks for Voting!) |
| Total Votes: | | 552 |
